학술논문
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Document Type
article
Author
Utz Krug; Anja Koschmieder; Daniela Schwammbach; Joachim Gerss; Nicola Tidow; Björn Steffen; Gesine Bug; Christian H Brandts; Markus Schaich; Christoph Röllig; Christian Thiede; Richard Noppeney; Matthias Stelljes; Thomas Büchner; Steffen Koschmieder; Ulrich Dührsen; Hubert Serve; Gerhard Ehninger; Wolfgang E Berdel; Carsten Müller-Tidow
Source
PLoS ONE, Vol 7, Iss 12, p e52695 (2012)
Subject
Language
English
ISSN
1932-6203
Abstract
Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML.Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of